Onset and Duration of Action of Formoterol and Tiotropium in Patients with Moderate to Severe COPD
- 1 June 2006
- journal article
- research article
- Published by S. Karger AG in Respiration
- Vol. 73 (4), 414-419
- https://doi.org/10.1159/000091996
Abstract
Background: Chronic obstructive pulmonary disease (COPD) management guidelines recommend regular treatment with one or more long-acting bronchodilators for patients with moderate to severe COPD. Objective: To compare the onset and duration of action of formoterol and tiotropium in patients with COPD. Methods: This randomized, multicentre, open-label crossover study in 38 patients with COPD (mean age 64 years; mean FEV1 55% predicted) assessed the effect of 7 days of treatment with formoterol (12 µg b.i.d. via Foradil® Aerolizer®) vs. tiotropium (18 µg o.d. via Spiriva® HandiHaler®) on lung function measured over a period of 12 h after the first dose on day 1 and the last dose on day 8. Results: The primary efficacy variable, FEV1-AUC during the first 2 h post-dose (FEV1-AUC10–120 min), was significantly higher for formoterol compared with tiotropium, with between-treatment differences of 124 ml (p = 0.016) after the first dose and 80 ml (p = 0.036) after 7 days’ treatment in favour of formoterol. FEV1 measured 12 h after inhalation did not differ statistically significantly between treatments. Adverse events occurred in 2 (5%) patients after treatment with formoterol and in 5 (12%) patients after treatment with tiotropium. Conclusion: This study demonstrates faster onset of action and greater bronchodilation of formoterol vs. tiotropium for bronchodilation within the first 2 h of inhalation (FEV1-AUC10–120 min) and comparable bronchodilation 12 h post-inhalation in patients with moderate to severe COPD.Keywords
This publication has 17 references indexed in Scilit:
- The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPDPulmonary Pharmacology & Therapeutics, 2003
- Bodyplethysmographischer Wirkeintritt von Formoterol bei Patienten mit mittel- bis schwergradiger partiell reversibler AtemwegsobstruktionPneumologie, 2002
- ATS StatementAmerican Journal of Respiratory and Critical Care Medicine, 2002
- The Spirometric Efficacy of Once-Daily Dosing With Tiotropium in Stable COPDSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2000
- Long-Acting Bronchodilation with Once-Daily Dosing of Tiotropium (Spiriva) in Stable Chronic Obstructive Pulmonary DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2000
- Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of actionEuropean Respiratory Journal, 1996
- Standardization of Spirometry, 1994 Update. American Thoracic Society.American Journal of Respiratory and Critical Care Medicine, 1995
- Effect of Ba 679 BR, a novel long-acting anticholinergic agent, on cholinergic neurotransmission in guinea pig and human airways.American Journal of Respiratory and Critical Care Medicine, 1994
- Pulmonary rehabilitation in chronic respiratory insufficiency. 7. Health-related quality of life among patients with chronic obstructive pulmonary disease.Thorax, 1994
- The Measurement of DyspneaSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 1984